Operator
Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NEXGEL’s Shareholder Update Conference Call.
I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications for introductions. Please go ahead.
Valter Pinto
Kanan, Corbin, Schupak & Aronow, Inc.
Thank you, operator. Good afternoon, and welcome, everyone, to NEXGEL’s Shareholder Update Conference Call. I’m joined today by Adam Levy, Chief Executive Officer. Before we begin, I’d like to remind everyone that statements made during today’s conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors.
For a detailed discussion of some of the ongoing risks and uncertainties in the company’s business, I refer you to our filings with the SEC filed periodically. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.
With that, it’s my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead.
Adam Levy
CEO, President & Director
Thank you, Valter, and thank you, everyone, for joining. On today’s call, I will discuss our announcement this morning regarding the closing of our transaction to acquire Celularity’s degenerative wound segment. This is a transformational step forward for our company, marking our evolution into a more scalable, diversified medical technology business, tripling our revenue run rate
Credit: Source link
